{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:49:24Z","timestamp":1785876564915,"version":"3.56.0"},"reference-count":126,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UKRI | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V029975\/1"],"award-info":[{"award-number":["MR\/V029975\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroblastoma is a common solid tumour in children and accounts for a disproportionate share of childhood cancer mortality. High-risk neuroblastoma is a major clinical challenge, with survival rates below 50% despite intensive therapy. Amplification of the MYCN oncogene is a hallmark of high-risk disease. MYCN protein is a transcription factor that promotes proliferation and blocks differentiation. MYCN is often described as \u2018undruggable\u2019 due to its lack of enzymatic activity and intrinsically disordered nature that means it lacks well-defined binding pockets for small molecules. This review explores the molecular interactome of MYCN as an opportunity for therapeutic discovery. We highlight functional and structural features of the interactions with key partners, such as MAX, WDR5, TFIIIC5 and Aurora kinase A. We discuss emerging strategies to disrupt MYCN interactions and to enable its degradation through disruption of protein stabilisation mechanisms or the use of degraders such as proteolysis targeting chimeras. By integrating knowledge of MYCN biology, molecular structures and chemical biology, these approaches provide promising routes towards targeted therapies for MYCN-driven neuroblastoma.<\/jats:p>","DOI":"10.1042\/bsr20250104","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:52:34Z","timestamp":1780494754000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the MYCN interaction network in neuroblastoma"],"prefix":"10.1042","volume":"46","author":[{"given":"Chelsea\u00a0Xinyi","family":"Yow","sequence":"first","affiliation":[{"name":"1School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-1405","authenticated-orcid":false,"given":"Sharon","family":"Yeoh","sequence":"additional","affiliation":[{"name":"1School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, U.K."},{"name":"2Astbury Centre for Structural Molecular Biology, University of Leeds, LS2 9JT, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Leen","sequence":"additional","affiliation":[{"name":"1School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, U.K."},{"name":"2Astbury Centre for Structural Molecular Biology, University of Leeds, LS2 9JT, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0604-2773","authenticated-orcid":false,"given":"Richard","family":"Bayliss","sequence":"additional","affiliation":[{"name":"1School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, U.K."},{"name":"2Astbury Centre for Structural Molecular Biology, University of Leeds, LS2 9JT, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026061501560865600_B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.sempedsurg.2011.10.009","article-title":"Neuroblastoma","volume":"21","author":"Davidoff","year":"2012","journal-title":"Semin. Pediatr. Surg."},{"key":"2026061501560865600_B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00043426-199205000-00004","article-title":"Molecular basis of clinical heterogeneity in neuroblastoma","volume":"14","author":"Brodeur","year":"1992","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"2026061501560865600_B3","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat. Rev. Dis. Primers."},{"key":"2026061501560865600_B4","doi-asserted-by":"publisher","first-page":"102964","DOI":"10.1016\/j.eclinm.2024.102964","article-title":"Global, regional, and national epidemiology of childhood neuroblastoma (1990\u20132021): a statistical analysis of incidence, mortality, and DALYs","volume":"79","author":"Nong","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026061501560865600_B5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.yapd.2011.03.011","article-title":"Neuroblastoma","volume":"58","author":"Colon","year":"2011","journal-title":"Adv. Pediatr."},{"key":"2026061501560865600_B6","doi-asserted-by":"publisher","first-page":"j1863","DOI":"10.1136\/bmj.j1863","article-title":"Neuroblastoma","volume":"357","author":"Shohet","year":"2017","journal-title":"BMJ"},{"key":"2026061501560865600_B7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/cncr.11521","article-title":"Neuroblastoma in adolescents","volume":"98","author":"Gaspar","year":"2003","journal-title":"Cancer"},{"key":"2026061501560865600_B8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.currproblcancer.2009.12.001","article-title":"Neuroblastoma","volume":"33","author":"Esiashvili","year":"2009","journal-title":"Curr. Probl. Cancer."},{"key":"2026061501560865600_B9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2026061501560865600_B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00441-018-2821-2","article-title":"Neuroblastoma: clinical and biological approach to risk stratification and treatment","volume":"372","author":"Tolbert","year":"2018","journal-title":"Cell Tissue Res."},{"key":"2026061501560865600_B11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","article-title":"The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report","volume":"27","author":"Monclair","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2026061501560865600_B12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1259\/bjr\/31861984","article-title":"Clinical presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of imaging algorithm","volume":"84","author":"Chu","year":"2011","journal-title":"Br. J. Radiol."},{"key":"2026061501560865600_B13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jcp.57.1.14","article-title":"Micrometastases in neuroblastoma: are they clinically important?","volume":"57","author":"Burchill","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"2026061501560865600_B14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00043426-199905000-00005","article-title":"Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival","volume":"21","author":"DuBois","year":"1999","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"2026061501560865600_B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.hoc.2009.11.011","article-title":"Neuroblastoma: biology, prognosis, and treatment","volume":"24","author":"Park","year":"2010","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2026061501560865600_B16","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1200\/JCO.21.00278","article-title":"Revised neuroblastoma risk classification system: a report from the children\u2019s oncology group","volume":"39","author":"Irwin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"2026061501560865600_B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349783","article-title":"High-risk and relapsed neuroblastoma: toward more cures and better outcomes","volume":"42","author":"DuBois","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"2026061501560865600_B18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12935-017-0412-z","article-title":"MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma","volume":"17","author":"Yue","year":"2017","journal-title":"Cancer Cell Int."},{"key":"2026061501560865600_B19","doi-asserted-by":"publisher","first-page":"1268275","DOI":"10.3389\/fcell.2023.1268275","article-title":"MYC function and regulation in physiological perspective","volume":"11","author":"Jha","year":"2023","journal-title":"Front Cell Dev. Biol."},{"key":"2026061501560865600_B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"2026061501560865600_B21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.trecan.2018.10.003","article-title":"The MYC enhancer-ome: long-range transcriptional regulation of MYC in cancer","volume":"4","author":"Lancho","year":"2018","journal-title":"Trends Cancer"},{"key":"2026061501560865600_B22","first-page":"282.e2","article-title":"Pan-cancer alterations of the MYC oncogene and its proximal network across the Cancer Genome Atlas","volume":"6","author":"Schaub","year":"2018","journal-title":"Cell Syst."},{"key":"2026061501560865600_B23","doi-asserted-by":"publisher","first-page":"e52483","DOI":"10.7554\/eLife.52483","article-title":"Dissecting transcriptional amplification by MYC","volume":"9","author":"Nie","year":"2020","journal-title":"Elife"},{"key":"2026061501560865600_B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"2026061501560865600_B25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell"},{"key":"2026061501560865600_B26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","article-title":"MYC protein interactors in gene transcription and cancer","volume":"21","author":"Lourenco","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"2026061501560865600_B27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/genes8040113","article-title":"The MYCN protein in health and disease","volume":"8","author":"Ruiz-Perez","year":"2017","journal-title":"Genes (Basel)"},{"key":"2026061501560865600_B28","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1073\/pnas.0911060107","article-title":"Stem cell-specific activation of an ancestral myc protooncogene with conserved basic functions in the early metazoan Hydra","volume":"107","author":"Hartl","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026061501560865600_B29","doi-asserted-by":"publisher","first-page":"a014415","DOI":"10.1101\/cshperspect.a014415","article-title":"Neuroblastoma and MYCN","volume":"3","author":"Huang","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2026061501560865600_B30","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/319780a0","article-title":"Differential expression of myc family genes during murine development","volume":"319","author":"Zimmerman","year":"1986","journal-title":"Nature"},{"key":"2026061501560865600_B31","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1101\/gad.14.11.1390","article-title":"N-MYC can functionally replace c-MYC in murine development, cellular growth, and differentiation","volume":"14","author":"Malynn","year":"2000","journal-title":"Genes Dev."},{"key":"2026061501560865600_B32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/2159-8290.CD-17-0273","article-title":"The Expanding World of N-MYC-Driven Tumors","volume":"8","author":"Rickman","year":"2018","journal-title":"Cancer Discov."},{"key":"2026061501560865600_B33","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-20-3108","article-title":"Drugging the \u201cundruggable\u201d MYCN oncogenic transcription factor: overcoming previous obstacles to impact childhood cancers","volume":"81","author":"Wolpaw","year":"2021","journal-title":"Cancer Res."},{"key":"2026061501560865600_B34","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1126\/science.6719137","article-title":"Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage","volume":"224","author":"Brodeur","year":"1984","journal-title":"Science"},{"key":"2026061501560865600_B35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/308288a0","article-title":"Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc","volume":"308","author":"Schwab","year":"1984","journal-title":"Nature"},{"key":"2026061501560865600_B36","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1073\/pnas.91.12.5523","article-title":"MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells","volume":"91","author":"Corvi","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026061501560865600_B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/geno.1996.0081","article-title":"High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas","volume":"32","author":"Reiter","year":"1996","journal-title":"Genomics"},{"key":"2026061501560865600_B38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/(SICI)1098-2264(199810)23:2%3c134::AID-GCC6%3e3.0.CO;2-3","article-title":"MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas","volume":"23","author":"Reiter","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"2026061501560865600_B39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.20517\/cdr.2019.009","article-title":"Targeting MYCN and ALK in resistant and relapsing neuroblastoma","volume":"2","author":"Tucker","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"2026061501560865600_B40","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1038\/s41467-020-19452-y","article-title":"Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma","volume":"11","author":"Helmsauer","year":"2020","journal-title":"Nat. Commun."},{"key":"2026061501560865600_B41","doi-asserted-by":"publisher","first-page":"12664","DOI":"10.1073\/pnas.0401083101","article-title":"Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification","volume":"101","author":"Hansford","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026061501560865600_B42","doi-asserted-by":"publisher","first-page":"624079","DOI":"10.3389\/fonc.2020.624079","article-title":"MYCN function in neuroblastoma development","volume":"10","author":"Otte","year":"2020","journal-title":"Front Oncol."},{"key":"2026061501560865600_B43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-022-02281-w","article-title":"Recent advances in the developmental origin of neuroblastoma: an overview","volume":"41","author":"Ponzoni","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2026061501560865600_B44","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1242\/dev.124.10.1953","article-title":"Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation","volume":"124","author":"Wakamatsu","year":"1997","journal-title":"Development"},{"key":"2026061501560865600_B45","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1101\/gad.1021202","article-title":"N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation","volume":"16","author":"Knoepfler","year":"2002","journal-title":"Genes Dev."},{"key":"2026061501560865600_B46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.diff.2010.05.001","article-title":"myc maintains embryonic stem cell pluripotency and self-renewal","volume":"80","author":"Varlakhanova","year":"2010","journal-title":"Differentiation"},{"key":"2026061501560865600_B47","doi-asserted-by":"publisher","first-page":"570815","DOI":"10.3389\/fonc.2020.570815","article-title":"The role of MYCN in symmetric vs. asymmetric cell division of human neuroblastoma cells","volume":"10","author":"Izumi","year":"2020","journal-title":"Front Oncol."},{"key":"2026061501560865600_B48","doi-asserted-by":"publisher","first-page":"18048","DOI":"10.1073\/pnas.1205525109","article-title":"Evidence of asymmetric cell division and centrosome inheritance in human neuroblastoma cells","volume":"109","author":"Izumi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026061501560865600_B49","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1016\/j.celrep.2017.11.090","article-title":"Association with Aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle","volume":"21","author":"Buchel","year":"2017","journal-title":"Cell Rep."},{"key":"2026061501560865600_B50","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.molcel.2018.09.031","article-title":"MYC protein interactome profiling reveals functionally distinct regions that cooperate to drive tumorigenesis","volume":"72","author":"Kalkat","year":"2018","journal-title":"Mol. Cell"},{"key":"2026061501560865600_B51","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1002\/j.1460-2075.1987.tb02657.x","article-title":"Structure and expression of the murine L-myc gene","volume":"6","author":"Legouy","year":"1987","journal-title":"EMBO J."},{"key":"2026061501560865600_B52","doi-asserted-by":"publisher","first-page":"gkag181","DOI":"10.1093\/nar\/gkag181","article-title":"Mechanism of interaction between the transactivation domain of N-MYC and the DNA-binding surface of TFIIIC5","volume":"54","author":"Leen","year":"2026","journal-title":"Nucleic. Acids. Res."},{"key":"2026061501560865600_B53","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.1073\/pnas.1610626113","article-title":"Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors","volume":"113","author":"Richards","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026061501560865600_B54","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/nar\/gkac138","article-title":"The MYC oncoprotein directly interacts with its chromatin cofactor PNUTS to recruit PP1 phosphatase","volume":"50","author":"Wei","year":"2022","journal-title":"Nucleic. Acids. Res."},{"key":"2026061501560865600_B55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.devcel.2005.07.014","article-title":"The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors","volume":"9","author":"Sjostrom","year":"2005","journal-title":"Dev. Cell"},{"key":"2026061501560865600_B56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1242\/dev.00891","article-title":"Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors","volume":"131","author":"Kenney","year":"2004","journal-title":"Development"},{"key":"2026061501560865600_B57","doi-asserted-by":"publisher","first-page":"eadm9449","DOI":"10.1126\/sciadv.adm9449","article-title":"The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma","volume":"10","author":"Malone","year":"2024","journal-title":"Sci. Adv."},{"key":"2026061501560865600_B58","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0969-2126(00)00107-6","article-title":"Crystallographic analysis of the specific yet versatile recognition of distinct nuclear localization signals by karyopherin alpha","volume":"8","author":"Conti","year":"2000","journal-title":"Structure"},{"key":"2026061501560865600_B59","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/onc.2015.416","article-title":"Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif","volume":"35","author":"Thomas","year":"2016","journal-title":"Oncogene"},{"key":"2026061501560865600_B60","doi-asserted-by":"publisher","first-page":"e3002240","DOI":"10.1371\/journal.pbio.3002240","article-title":"MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription","volume":"22","author":"Liu","year":"2024","journal-title":"PLoS Biol."},{"key":"2026061501560865600_B61","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molcel.2015.02.028","article-title":"Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC","volume":"58","author":"Thomas","year":"2015","journal-title":"Mol. Cell"},{"key":"2026061501560865600_B62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0092-8674(02)01284-9","article-title":"X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors","volume":"112","author":"Nair","year":"2003","journal-title":"Cell"},{"key":"2026061501560865600_B63","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/acs.biochem.9b00296","article-title":"Crystal structures and nuclear magnetic resonance studies of the Apo form of the c-MYC:MAX bHLHZip complex reveal a helical basic region in the absence of DNA","volume":"58","author":"Sammak","year":"2019","journal-title":"Biochemistry"},{"key":"2026061501560865600_B64","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/35070076","article-title":"Repression of p15INK4b expression by Myc through association with Miz-1","volume":"3","author":"Staller","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"2026061501560865600_B65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ccell.2015.12.003","article-title":"The interaction of Myc with Miz1 defines medulloblastoma subgroup identity","volume":"29","author":"Vo","year":"2016","journal-title":"Cancer Cell"},{"key":"2026061501560865600_B66","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1093\/nar\/gks263","article-title":"Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding","volume":"40","author":"Andresen","year":"2012","journal-title":"Nucleic. Acids. Res."},{"key":"2026061501560865600_B67","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1042\/BCJ20240248","article-title":"Exploring the dynamics and interactions of the N-myc transactivation domain through solution nuclear magnetic resonance spectroscopy","volume":"481","author":"Rejnowicz","year":"2024","journal-title":"Biochem. J."},{"key":"2026061501560865600_B68","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.str.2015.10.010","article-title":"Pre-anchoring of Pin1 to unphosphorylated c-Myc in a fuzzy complex regulates c-Myc activity","volume":"23","author":"Helander","year":"2015","journal-title":"Structure"},{"key":"2026061501560865600_B69","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0092-8674(91)90457-A","article-title":"Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation","volume":"65","author":"Prendergast","year":"1991","journal-title":"Cell"},{"key":"2026061501560865600_B70","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1126\/science.2006410","article-title":"Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc","volume":"251","author":"Blackwood","year":"1991","journal-title":"Science"},{"key":"2026061501560865600_B71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0959-437X(94)90098-1","article-title":"Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death","volume":"4","author":"Amati","year":"1994","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2026061501560865600_B72","first-page":"1783","article-title":"Max and c-Myc\/Max DNA-binding activities in cell extracts","volume":"7","author":"Littlewood","year":"1992","journal-title":"Oncogene"},{"key":"2026061501560865600_B73","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/359423a0","article-title":"Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max","volume":"359","author":"Amati","year":"1992","journal-title":"Nature"},{"key":"2026061501560865600_B74","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/bjc.2015.360","article-title":"Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis","volume":"113","author":"Wilde","year":"2015","journal-title":"Br. J. Cancer"},{"key":"2026061501560865600_B75","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1073\/pnas.88.10.4323","article-title":"Sequence-specific DNA binding by Myc proteins","volume":"88","author":"Kerkhoff","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026061501560865600_B76","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bbagen.2003.12.007","article-title":"Determination of binding constant of transcription factor myc-max\/max-max and E-box DNA: the effect of inhibitors on the binding","volume":"1670","author":"Park","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"2026061501560865600_B77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/B978-0-12-380916-2.00004-8","article-title":"The connections between neural crest development and neuroblastoma","volume":"94","author":"Jiang","year":"2011","journal-title":"Curr. Top. Dev. Biol."},{"key":"2026061501560865600_B78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbagrm.2018.01.007","article-title":"MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma","volume":"1861","author":"Ferrucci","year":"2018","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"2026061501560865600_B79","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","article-title":"Aurora A kinase (AURKA) in normal and pathological cell division","volume":"70","author":"Nikonova","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"2026061501560865600_B80","first-page":"307","article-title":"Ubiquitin-mediated degradation of Aurora kinases","volume":"5","author":"Lindon","year":"2015","journal-title":"Front Oncol."},{"key":"2026061501560865600_B81","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbcan.2010.08.001","article-title":"The Aurora-A\/TPX2 complex: a novel oncogenic holoenzyme?","volume":"1806","author":"Asteriti","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"2026061501560865600_B82","first-page":"4450","article-title":"Human proto-oncogene N-myc encodes nuclear proteins that bind DNA","volume":"6","author":"Ramsay","year":"1986","journal-title":"Mol. Cell. Biol."},{"key":"2026061501560865600_B83","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1073\/pnas.0402770101","article-title":"The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation","volume":"101","author":"Welcker","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026061501560865600_B84","doi-asserted-by":"publisher","first-page":"eabl7872","DOI":"10.1126\/sciadv.abl7872","article-title":"Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor","volume":"8","author":"Welcker","year":"2022","journal-title":"Sci. Adv."},{"key":"2026061501560865600_B85","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"2026061501560865600_B86","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41594-019-0321-z","article-title":"Multiple direct interactions of TBP with the MYC oncoprotein","volume":"26","author":"Wei","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2026061501560865600_B87","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41467-026-69725-1","article-title":"The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A","volume":"17","author":"Hultman","year":"2026","journal-title":"Nat. Commun."},{"key":"2026061501560865600_B88","doi-asserted-by":"publisher","first-page":"352.e10","DOI":"10.1016\/j.chembiol.2024.12.006","article-title":"Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders","volume":"32","author":"Tang","year":"2025","journal-title":"Cell. Chem. Biol."},{"key":"2026061501560865600_B89","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s43018-020-00171-8","article-title":"Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma","volume":"2","author":"Roeschert","year":"2021","journal-title":"Nat. Cancer."},{"key":"2026061501560865600_B90","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1042\/BST20253058","article-title":"Should I stay or should I go: TFIIIC as assembly factor and barrier in RNA polymerase III transcription","volume":"53","author":"Seifert-Davila","year":"2025","journal-title":"Biochem. Soc. Trans."},{"key":"2026061501560865600_B91","doi-asserted-by":"publisher","first-page":"RP94407","DOI":"10.7554\/eLife.94407","article-title":"Association with TFIIIC limits MYCN localisation in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA polymerase II","volume":"13","author":"Vidal","year":"2024","journal-title":"Elife"},{"key":"2026061501560865600_B92","doi-asserted-by":"publisher","first-page":"159.e12","DOI":"10.1016\/j.molcel.2021.11.002","article-title":"MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts","volume":"82","author":"Papadopoulos","year":"2022","journal-title":"Mol. Cell"},{"key":"2026061501560865600_B93","doi-asserted-by":"publisher","first-page":"e97285","DOI":"10.1371\/journal.pone.0097285","article-title":"Targeting of the MYCN protein with small molecule c-MYC inhibitors","volume":"9","author":"Muller","year":"2014","journal-title":"PloS ONE"},{"key":"2026061501560865600_B94","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.chembiol.2008.09.011","article-title":"Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules","volume":"15","author":"Follis","year":"2008","journal-title":"Chem. Biol."},{"key":"2026061501560865600_B95","doi-asserted-by":"publisher","first-page":"483.e15","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"2026061501560865600_B96","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/sj.onc.1202199","article-title":"Design and properties of a Myc derivative that efficiently homodimerizes","volume":"17","author":"Soucek","year":"1998","journal-title":"Oncogene"},{"key":"2026061501560865600_B97","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat. Med."},{"key":"2026061501560865600_B98","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nchembio.1859","article-title":"Pharmacological targeting of the Wdr5-MLL interaction in C\/EBPalpha N-terminal leukemia","volume":"11","author":"Grebien","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"2026061501560865600_B99","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1021\/acschembio.2c00843","article-title":"Discovery of potent small-molecule inhibitors of WDR5-MYC interaction","volume":"18","author":"Ding","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"2026061501560865600_B100","doi-asserted-by":"publisher","first-page":"8310","DOI":"10.1021\/acs.jmedchem.3c00787","article-title":"Discovery and structure-based design of inhibitors of the WD repeat-containing protein 5 (WDR5)-MYC interaction","volume":"66","author":"Ding","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026061501560865600_B101","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41401-022-00999-z","article-title":"Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"2026061501560865600_B102","doi-asserted-by":"publisher","first-page":"djv080","DOI":"10.1093\/jnci\/djv080","article-title":"The role of histone demethylase KDM4B in Myc signaling in neuroblastoma","volume":"107","author":"Yang","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"2026061501560865600_B103","doi-asserted-by":"publisher","first-page":"101468","DOI":"10.1016\/j.xcrm.2024.101468","article-title":"Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma","volume":"5","author":"Abu-Zaid","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2026061501560865600_B104","doi-asserted-by":"publisher","first-page":"14572","DOI":"10.18632\/oncotarget.3990","article-title":"Lysine-specific demethylase (LSD1\/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma","volume":"6","author":"Amente","year":"2015","journal-title":"Oncotarget"},{"key":"2026061501560865600_B105","doi-asserted-by":"publisher","first-page":"114818","DOI":"10.1016\/j.ejmech.2022.114818","article-title":"Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma","volume":"244","author":"Mills","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2026061501560865600_B106","doi-asserted-by":"publisher","first-page":"578770","DOI":"10.3389\/fcell.2020.578770","article-title":"Histone deacetylases and histone deacetylase inhibitors in neuroblastoma","volume":"8","author":"Phimmachanh","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"key":"2026061501560865600_B107","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/0008-5472.CAN-10-2627","article-title":"A SP1\/MIZ1\/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF","volume":"71","author":"Iraci","year":"2011","journal-title":"Cancer Res."},{"key":"2026061501560865600_B108","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.febslet.2005.01.058","article-title":"Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins","volume":"579","author":"Ouwehand","year":"2005","journal-title":"FEBS Lett."},{"key":"2026061501560865600_B109","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.chembiol.2013.03.020","article-title":"Selective HDAC1\/HDAC2 inhibitors induce neuroblastoma differentiation","volume":"20","author":"Frumm","year":"2013","journal-title":"Chem. Biol."},{"key":"2026061501560865600_B110","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/s41388-021-01712-w","article-title":"A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma","volume":"40","author":"Cheung","year":"2021","journal-title":"Oncogene"},{"key":"2026061501560865600_B111","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1042\/BJ20091530","article-title":"Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design","volume":"427","author":"Dodson","year":"2010","journal-title":"Biochem. J."},{"key":"2026061501560865600_B112","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccr.2013.05.005","article-title":"Small molecule inhibitors of Aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma","volume":"24","author":"Brockmann","year":"2013","journal-title":"Cancer Cell"},{"key":"2026061501560865600_B113","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ccr.2014.07.015","article-title":"Drugging MYCN through an allosteric transition in Aurora kinase A","volume":"26","author":"Gustafson","year":"2014","journal-title":"Cancer Cell"},{"key":"2026061501560865600_B114","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-18-2675","article-title":"A phase II atudy of alisertib in children with recurrent\/refractory solid tumors or leukemia: children\u2019s oncology group Phase I and Pilot Consortium (ADVL0921)","volume":"25","author":"Mosse","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026061501560865600_B115","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-18-1381","article-title":"Phase II trial of alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma","volume":"24","author":"DuBois","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2026061501560865600_B116","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1535-7163.MCT-23-0602","article-title":"Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus","volume":"23","author":"Chang","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"2026061501560865600_B117","doi-asserted-by":"publisher","first-page":"e202300649","DOI":"10.1002\/cbic.202300649","article-title":"Inhibition of Aurora-A\/N-Myc protein\u2013protein interaction using peptidomimetics: understanding the role of peptide cyclization","volume":"25","author":"Dawber","year":"2024","journal-title":"ChemBioChem"},{"key":"2026061501560865600_B118","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1039\/D4SC06100D","article-title":"Constrained TACC3 peptidomimetics for a non-canonical protein\u2013protein interface elucidate allosteric communication in Aurora-A kinase","volume":"16","author":"Gimenez","year":"2024","journal-title":"Chem. Sci."},{"key":"2026061501560865600_B119","doi-asserted-by":"publisher","first-page":"1714.e10","DOI":"10.1016\/j.cell.2020.10.038","article-title":"Mapping the degradable kinome provides a resource for expedited degrader development","volume":"183","author":"Donovan","year":"2020","journal-title":"Cell"},{"key":"2026061501560865600_B120","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41589-020-00652-y","article-title":"PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase","volume":"16","author":"Adhikari","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"2026061501560865600_B121","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s42003-021-02158-2","article-title":"Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool","volume":"4","author":"Wang","year":"2021","journal-title":"Commun. Biol."},{"key":"2026061501560865600_B122","doi-asserted-by":"publisher","first-page":"115033","DOI":"10.1016\/j.ejmech.2022.115033","article-title":"Targeted AURKA degradation: towards new therapeutic agents for neuroblastoma","volume":"247","author":"Rishfi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2026061501560865600_B123","doi-asserted-by":"publisher","first-page":"23962","DOI":"10.1021\/acs.jmedchem.5c01271","article-title":"Second-generation AURKA-targeting PROTACs: structural optimization toward in vivo degradation in neuroblastoma","volume":"68","author":"Krols","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026061501560865600_B124","doi-asserted-by":"publisher","first-page":"eabj1578","DOI":"10.1126\/scitranslmed.abj1578","article-title":"A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models","volume":"13","author":"Yu","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"2026061501560865600_B125","doi-asserted-by":"publisher","first-page":"574525","DOI":"10.3389\/fonc.2020.574525","article-title":"PROTAC bromodomain inhibitor ARV-825 displays anti-tumor activity in neuroblastoma by repressing expression of MYCN or c-Myc","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol."},{"key":"2026061501560865600_B126","doi-asserted-by":"publisher","first-page":"e2104344","DOI":"10.1002\/advs.202104344","article-title":"A selective small-molecule c-Myc degrader potently regresses lethal c-Myc overexpressing tumors","volume":"9","author":"Xu","year":"2022","journal-title":"Adv. Sci. (Weinh)"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20250104\/988771\/bsr-2025-0104c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20250104\/988771\/bsr-2025-0104c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:56:14Z","timestamp":1781502974000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/46\/6\/BSR20250104\/237655\/Targeting-the-MYCN-interaction-network-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20250104","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"BSR20250104"}}